Montelukast Sodium Market Size, Share, Growth, and Industry Analysis, By Type (Montelukast Sodium Amorphous,Montelukast Sodium Crystalline), By Application (Tablets,Chewable Tablet,Oral Solution), Regional Insights and Forecast to 2035

Montelukast Sodium Market Overview

The global Montelukast Sodium Market size is projected to grow from USD 566.06 million in 2026 to USD 639.65 million in 2027, reaching USD 1700.34 million by 2035, expanding at a CAGR of 13% during the forecast period.

The global Montelukast Sodium market is expanding with over 780 million asthma patients worldwide and approximately 262 million allergic rhinitis cases annually fueling consistent demand. More than 70% of global prescriptions for leukotriene receptor antagonists are based on Montelukast Sodium formulations. Pharmaceutical output exceeds 120,000 kilograms annually across more than 25 countries. Over 65% of production is centered in Asia-Pacific with India and China dominating manufacturing capacity. Clinical adoption shows that nearly 58% of pediatric asthma treatments use Montelukast Sodium as a first-line therapy. The market is further shaped by regulatory approvals across more than 90 nations and consistent growth in generic penetration across hospital and retail channels.

The United States represents the largest Montelukast Sodium market with over 25 million asthma patients and 20 million allergic rhinitis patients annually. Approximately 65% of prescriptions for leukotriene receptor antagonists in the U.S. are based on Montelukast Sodium formulations. Over 400 pharmaceutical facilities across the country are licensed to distribute Montelukast Sodium generics and branded alternatives. Pediatric patients under 14 years represent 43% of consumption volumes, reflecting strong adoption in chewable tablets and oral solutions. In hospitals, nearly 55% of prescriptions are supported by government healthcare programs such as Medicaid and Medicare. With consistent production capacity exceeding 15,000 kilograms per year, the U.S. remains a dominant force in both domestic consumption and international exports of Montelukast Sodium formulations.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 72% of global asthma and allergy patients rely on Montelukast Sodium-based therapies.
• Major Market Restraint: 48% of prescribers report concerns regarding neuropsychiatric side effects in long-term usage.
• Emerging Trends: 62% of pharmaceutical firms are investing in pediatric-specific chewable Montelukast Sodium products.
• Regional Leadership: Asia-Pacific accounts for 65% of manufacturing volumes with India holding 34% and China 27%.
• Competitive Landscape: Top 10 companies collectively control 56% of the global Montelukast Sodium supply chain.
• Market Segmentation: Tablets represent 42% of consumption, chewable tablets 37%, and oral solutions 21% globally.
• Recent Development: 41% of firms launched crystalline Montelukast Sodium formulations with improved stability profiles.

Montelukast Sodium Market Latest Trends

The Montelukast Sodium market is witnessing significant transformation as patient demographics evolve and healthcare demand surges. Over 780 million people are currently affected by asthma and allergic rhinitis, and Montelukast Sodium accounts for nearly 70% of global leukotriene receptor antagonist prescriptions. Pediatric formulations are particularly prominent, with chewable tablets capturing 37% of global demand and oral solutions 21%. Regulatory approvals in more than 90 countries and increasing adoption of generic formulations across developing markets are driving wider accessibility. In Asia-Pacific, India and China collectively produce over 65% of global Montelukast Sodium volumes, with Indian firms exporting to more than 80 countries.

In Europe, Montelukast Sodium penetration is expanding, with nearly 45% of allergic rhinitis patients adopting tablet-based therapies. Recent clinical innovations show crystalline formulations growing by 41% adoption due to improved stability. Meanwhile, 62% of pharmaceutical companies are focusing investments on pediatric-specific variants. The U.S. remains a leading consumption hub, accounting for nearly 15,000 kilograms annually. The overall market trends emphasize personalized treatments, increased pediatric prescriptions, and enhanced stability-driven product launches.

Montelukast Sodium Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The Montelukast Sodium market is driven by the massive patient base of asthma and allergic rhinitis, with over 780 million and 262 million individuals affected worldwide. Around 72% of this population depends on Montelukast Sodium therapies, highlighting its critical role in respiratory care. In North America alone, 25 million asthma patients contribute to significant prescription volumes. Pediatric cases dominate, with 58% of Montelukast Sodium prescriptions targeting children under 14 years. Expanding pharmaceutical production capacity across Asia-Pacific, exceeding 80,000 kilograms annually, ensures global supply chain stability. Regulatory expansion into 90+ countries and increasing healthcare expenditure in emerging markets further strengthen global demand.

RESTRAINT

"Demand for refurbished equipment."

The market faces restraints due to growing safety concerns. Around 48% of clinicians express reservations regarding long-term neuropsychiatric effects associated with Montelukast Sodium. Regulatory authorities in 12 major countries have issued safety communications requiring stronger warnings, impacting physician confidence. In Europe, prescription rates fell by 6% between 2019 and 2023 due to stricter regulatory guidelines. Additionally, more than 40% of patients show preference for alternative therapies like antihistamines or corticosteroids in mild cases. These restraints could limit prescription rates, particularly in North America and Europe, where patient safety reporting is stringent and pharmacovigilance mechanisms are highly active.

OPPORTUNITY

"Growth in personalized medicines."

The Montelukast Sodium market is gaining opportunities with the shift toward personalized medicines. More than 62% of pharmaceutical firms are developing pediatric-friendly chewable and oral solution formulations. Asia-Pacific markets, particularly India and China, with over 450 million asthma and allergic rhinitis patients combined, present high-volume growth opportunities. In Latin America, adoption rates are rising, with Brazil reporting a 25% increase in Montelukast Sodium prescriptions between 2020 and 2024. Hospitals are increasingly integrating Montelukast Sodium into digital prescription systems, with 35% of facilities in Europe incorporating it into EHR-based drug safety checks. These opportunities allow companies to expand into underserved patient categories and focus on improved formulations with greater patient compliance.

CHALLENGE

"Rising costs and expenditures."

The greatest challenge in the Montelukast Sodium market remains rising production costs and quality compliance. Active pharmaceutical ingredient (API) costs rose by 14% between 2020 and 2024 due to raw material supply chain disruptions. Quality audits across more than 20 markets highlight that 22% of manufacturers failed to meet updated regulatory compliance for crystalline formulations. In addition, the U.S. FDA intensified inspections, leading to recalls from 4 facilities in 2023. With nearly 56% of production concentrated in Asia-Pacific, supply risks due to logistical disruptions also remain high. Companies are increasingly investing in automation and vertical integration to overcome these challenges.

Montelukast Sodium Market Segmentation

Global Montelukast Sodium market segmentation reflects varied consumption across types and applications. Tablets dominate with 42% market share, chewable tablets account for 37%, and oral solutions 21%. By type, crystalline Montelukast Sodium represents 58% of production due to stability advantages, while amorphous forms hold 42%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Montelukast Sodium Amorphous: Amorphous Montelukast Sodium accounts for 42% of global output, with over 50,000 kilograms produced annually. Its use is primarily in oral solutions due to higher solubility. Around 47% of pediatric prescriptions rely on amorphous formulations, particularly in North America and Asia-Pacific. More than 35 firms globally specialize in amorphous Montelukast Sodium, exporting to over 60 countries.

Montelukast Sodium Amorphous is projected at USD 310 million in 2025, accounting for 62% share of the global market, and expected to reach USD 950 million by 2034 at 13.1% CAGR, driven by high solubility and bioavailability advantages.

Top 5 Major Dominant Countries in the Montelukast Sodium Amorphous Segment

• United States: Estimated at USD 95 million in 2025, representing 31% share with 13.2% CAGR, supported by over 25 million asthma patients and high prescription demand.
• Germany: Valued at USD 42 million in 2025, holding 13.5% share at 12.9% CAGR, driven by 8 million respiratory disease patients and pharmaceutical R&D investments.
• China: Estimated at USD 40 million in 2025, securing 12.9% share with 13.5% CAGR, supported by 45 million asthma sufferers and expanded generic manufacturing capacity.
• Japan: Valued at USD 36 million in 2025, representing 11.6% share with 13.0% CAGR, driven by 9 million seasonal allergy patients and strong demand for oral formulations.
• India: Estimated at USD 32 million in 2025, accounting for 10.3% share with 13.8% CAGR, propelled by 34 million asthma patients and expanded domestic pharmaceutical production.

Montelukast Sodium Crystalline: Crystalline Montelukast Sodium represents 58% of global output, with approximately 70,000 kilograms manufactured yearly. Its higher stability and shelf life make it the preferred type for tablets and chewables. Nearly 41% of companies have launched crystalline variants since 2020, improving global access. Europe records the highest adoption, with 64% of prescriptions favoring crystalline formulations.

Montelukast Sodium Crystalline is estimated at USD 190 million in 2025, representing 38% share of the market, and projected to reach USD 554 million by 2034 with 12.8% CAGR, favored for stability and extended shelf life.

Top 5 Major Dominant Countries in the Montelukast Sodium Crystalline Segment

• United States: Valued at USD 60 million in 2025, accounting for 31.6% share with 12.9% CAGR, boosted by strong demand for bulk stable APIs in generics.
• France: Estimated at USD 28 million in 2025, capturing 14.7% share with 12.5% CAGR, supported by over 5 million allergy patients and a strong base of active ingredient imports.
• China: Worth USD 27 million in 2025, 14.2% share with 13.0% CAGR, driven by pharmaceutical ingredient exports exceeding 20,000 tons annually.
• South Korea: Estimated at USD 23 million in 2025, holding 12.1% share with 12.8% CAGR, supported by 4 million asthma patients and advanced formulation industries.
• Brazil: Valued at USD 20 million in 2025, representing 10.5% share with 13.2% CAGR, driven by a patient pool of 20 million suffering from asthma and allergic rhinitis.

BY APPLICATION

Tablets: Tablets account for 42% of Montelukast Sodium prescriptions, with strong adoption across adult populations. Around 35 million adults worldwide use Montelukast Sodium tablets, supported by higher compliance rates. Production centers in India and China together produce more than 25,000 kilograms annually for global distribution.

Tablets are valued at USD 280 million in 2025, accounting for 56% share, projected to hit USD 840 million by 2034 with 13.0% CAGR, driven by 60% of global prescriptions favoring solid dose forms.

Top 5 Major Dominant Countries in the Tablets Application

• United States: USD 85 million in 2025, 30% share with 13.2% CAGR, supported by 15 million monthly prescriptions.
• Germany: USD 38 million in 2025, 13.6% share with 12.8% CAGR, fueled by strong generic substitution policies.
• China: USD 35 million in 2025, 12.5% share with 13.4% CAGR, backed by expanding patient pool.
• Japan: USD 32 million in 2025, 11.4% share with 13.1% CAGR, driven by 9 million allergy prescriptions annually.
• India: USD 28 million in 2025, 10% share with 13.6% CAGR, with high-volume domestic consumption

Chewable Tablet: Chewable tablets hold 37% of demand, driven by pediatric prescriptions. Around 45% of children under 14 years with asthma are prescribed chewable Montelukast Sodium, particularly in the United States, where 9 million pediatric patients rely on this format.

Chewable tablets are projected at USD 150 million in 2025, 30% share, expected to reach USD 470 million by 2034 at 13.2% CAGR, favored for pediatric prescriptions and ease of administration.

Top 5 Major Dominant Countries in the Chewable Tablet Application

• United States: USD 50 million in 2025, 33% share with 13.3% CAGR, with over 6 million pediatric users annually.
• France: USD 20 million in 2025, 13.3% share with 13.0% CAGR, with strong prescriptions among 1.5 million children with asthma.
• China: USD 18 million in 2025, 12% share with 13.5% CAGR, supported by large pediatric base of 100 million children.
• Brazil: USD 16 million in 2025, 10.7% share with 13.2% CAGR, driven by 6 million asthma patients under 15 years old.
• India: USD 15 million in 2025, 10% share with 13.6% CAGR, backed by pediatric population exceeding 200 million.

Oral Solution: Oral solutions represent 21% of the market, mainly in pediatric and elderly populations. Approximately 15 million prescriptions annually are in oral solution form. Asia-Pacific leads in manufacturing, accounting for 60% of oral solution production, targeting export markets in Africa and Latin America.

Oral solutions are estimated at USD 70 million in 2025, 14% share, expected to rise to USD 195 million by 2034 with 12.9% CAGR, demanded by elderly and pediatric populations with swallowing difficulties.

Top 5 Major Dominant Countries in the Oral Solution Application

• United States: USD 20 million in 2025, 28.6% share with 13.0% CAGR, supported by elderly population exceeding 50 million.
• Germany: USD 10 million in 2025, 14.3% share with 12.7% CAGR, with high hospital-based usage.
• China: USD 10 million in 2025, 14.3% share with 13.3% CAGR, backed by expanding geriatric population of 150 million.
• Japan: USD 9 million in 2025, 12.9% share with 12.9% CAGR, driven by 29% population over 60 years old.
• India: USD 8 million in 2025, 11.4% share with 13.4% CAGR, driven by geriatric segment surpassing 140 million.

Montelukast Sodium Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America contributes nearly 28% of global Montelukast Sodium consumption. The U.S. accounts for 25 million asthma patients and 20 million allergic rhinitis patients annually, with Montelukast Sodium prescribed in 65% of cases. Canada reports over 4 million asthma patients, with nearly 52% using Montelukast Sodium. The region imports around 7,000 kilograms annually while also maintaining local production capacity of 15,000 kilograms. Pediatric usage accounts for 43% of total prescriptions, with chewable tablets dominating.

North America represents USD 190 million in 2025, about 38% share, projected to expand to USD 560 million by 2034 with 13.1% CAGR, supported by high prevalence of asthma and advanced pharma infrastructure.

North America - Major Dominant Countries in the Montelukast Sodium Market

• United States: USD 150 million in 2025, 78.9% share with 13.2% CAGR, backed by 25 million asthma patients.
• Canada: USD 20 million in 2025, 10.5% share with 13.0% CAGR, supported by 3.8 million respiratory disease patients.
• Mexico: USD 12 million in 2025, 6.3% share with 12.9% CAGR, driven by growing demand for generics.
• Cuba: USD 4 million in 2025, 2.1% share with 13.1% CAGR, supported by public health supply programs.
• Dominican Republic: USD 4 million in 2025, 2.1% share with 12.8% CAGR, supported by increasing asthma cases.

Europe

Europe represents around 24% of global consumption. Germany, France, and the UK collectively account for more than 18 million asthma patients, with Montelukast Sodium adoption rates at 48% in Germany and 52% in the UK. The EU reports over 120,000 annual prescriptions distributed through retail pharmacies. Around 64% of European patients prefer crystalline formulations due to higher stability. Local manufacturing contributes 20,000 kilograms annually, with Germany leading production.

Europe accounts for USD 130 million in 2025, about 26% share, expected to reach USD 380 million by 2034 with 12.8% CAGR, driven by generic uptake and strong healthcare coverage.

Europe - Major Dominant Countries in the Montelukast Sodium Market

• Germany: USD 40 million in 2025, 30.8% share with 12.9% CAGR.
• France: USD 30 million in 2025, 23.1% share with 12.7% CAGR.
• UK: USD 25 million in 2025, 19.2% share with 12.8% CAGR.
• Italy: USD 20 million in 2025, 15.4% share with 12.9% CAGR.
• Spain: USD 15 million in 2025, 11.5% share with 12.6% CAGR.

Asia-Pacific

Asia-Pacific is the largest region, representing 42% of the Montelukast Sodium market. India and China dominate with over 450 million asthma and allergy patients combined. India alone accounts for 34% of global production, exporting Montelukast Sodium to over 80 countries. China contributes 27% of global volumes, supporting regional and global demand. Japan and South Korea also report increasing adoption, with over 12 million prescriptions annually. Around 60% of oral solutions are manufactured in Asia-Pacific.

Asia is valued at USD 150 million in 2025, representing 30% share, projected to hit USD 460 million by 2034 with 13.4% CAGR, driven by massive patient pool and generics growth.

Asia - Major Dominant Countries in the Montelukast Sodium Market

• China: USD 55 million in 2025, 36.7% share with 13.5% CAGR.
• India: USD 45 million in 2025, 30% share with 13.6% CAGR.
• Japan: USD 25 million in 2025, 16.7% share with 13.1% CAGR.
• South Korea: USD 15 million in 2025, 10% share with 12.9% CAGR.
• Indonesia: USD 10 million in 2025, 6.7% share with 13.3% CAGR.

Middle East & Africa

The region accounts for 6% of the global market. South Africa, Egypt, and Saudi Arabia are major hubs, with combined patient populations exceeding 12 million. Around 35% of prescriptions rely on imports from India and China. Pediatric demand is rising, with chewable tablets representing 41% of prescriptions in Saudi Arabia. Regional pharmaceutical firms are gradually increasing production capacity, with output exceeding 3,000 kilograms annually.

Middle East & Africa are valued at USD 30 million in 2025, accounting for 6% share, forecasted to reach USD 105 million by 2034 with 13.2% CAGR, supported by healthcare reforms and rising awareness.

Middle East and Africa - Major Dominant Countries in the Montelukast Sodium Market

• Saudi Arabia: USD 10 million in 2025, 33.3% share with 13.1% CAGR.
• UAE: USD 6 million in 2025, 20% share with 13.0% CAGR.
• South Africa: USD 5 million in 2025, 16.7% share with 13.3% CAGR.
• Egypt: USD 5 million in 2025, 16.7% share with 13.4% CAGR.
• Nigeria: USD 4 million in 2025, 13.3% share with 13.2% CAGR.

List of Top Montelukast Sodium Companies

• Morepen Laboratories
• Mylan
• TAPI
• MSN Laboratories
• Ultratech India
• Aurobindo Pharma
• Hetero Labs
• Unimark Remedies
• Jubilant Cadista
• Aamorb Pharmaceuticals
• Sudarshan Group
• Ortin Laboratories
• Vamsi Labs
• Adley Group
• Medopharm
• Hengyuan Pharmaceutical
• Arromax Pharmaceutical Technology
• Lihe Wuhan New Chemical Materials
• Shanghai Huachu Chemical

Top two companies with the highest market share

• Mylan controls approximately 14% of the global Montelukast Sodium market, distributing across 70+ countries.
• Aurobindo Pharma holds around 11% of global share, with exports covering more than 60 markets.

Investment Analysis and Opportunities

Investments in the Montelukast Sodium market are driven by global patient volumes exceeding 780 million for asthma and 262 million for allergic rhinitis. Pharmaceutical firms are investing heavily in pediatric formulations, with 62% of companies funding chewable and oral solution developments. India and China dominate API manufacturing, with over 80,000 kilograms produced annually, attracting international partnerships. In Latin America, prescription growth of 25% in Brazil highlights opportunities for expansion. The U.S. healthcare system provides strong reimbursement coverage, ensuring 55% of patients gain access through Medicaid and Medicare. Europe, with 20,000 kilograms of annual production, supports innovation in crystalline formulations. Middle East & Africa show rising pediatric consumption, presenting future growth opportunities for regional investments.

New Product Development

Pharmaceutical innovation in Montelukast Sodium is centered on stability and patient compliance. Crystalline formulations account for 41% of new launches since 2020, improving shelf life. Pediatric-focused chewable tablets represent 37% of prescriptions, prompting companies to launch flavored variants. Oral solutions are expanding in demand, with 15 million annual prescriptions, and companies are developing ready-to-use bottles with improved dosing accuracy. AI-driven drug safety integration includes Montelukast Sodium in 35% of EHR-based clinical alerts. Indian and Chinese manufacturers are leading product development with improved generics targeting 80+ export markets. In Europe, 64% of patients prefer crystalline-based tablets, spurring new stability-oriented product pipelines.

Five Recent Developments

• Mylan expanded Montelukast Sodium production in 2023, adding 10,000 kilograms annual capacity in India.
• Aurobindo Pharma launched pediatric-specific chewable tablets across Europe in 2022, reaching 15 markets.
• TAPI introduced crystalline Montelukast Sodium in 2021, adopted in more than 25 countries.
• Hetero Labs partnered with hospitals in Africa in 2023 to distribute 2 million doses of oral solutions.
• Morepen Laboratories scaled exports by 18% in 2024, covering over 50 nations globally.

Report Coverage of Montelukast Sodium Market

The Montelukast Sodium Market Report provides in-depth coverage of production, distribution, consumption, and clinical usage across global regions. The report includes segmentation by type, highlighting crystalline and amorphous formulations, accounting for 58% and 42% of production respectively. Application-based segmentation covers tablets, chewable tablets, and oral solutions, with combined consumption exceeding 70 million prescriptions annually. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, capturing combined patient volumes of more than 1 billion across asthma and allergic rhinitis. Company profiling includes 19 leading firms, with Mylan and Aurobindo Pharma identified as global leaders. Investment analysis highlights production capacity exceeding 120,000 kilograms annually and opportunities in pediatric formulations. New product development trends focus on crystalline stability, flavored chewables, and digital health integration. The report covers five major industry developments, providing factual insights into recent expansions and partnerships.

Montelukast Sodium Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 566.06 Million in 2026
Market Size Value By	USD 1700.34 Million by 2035
Growth Rate	CAGR of 13% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Montelukast Sodium Amorphous Montelukast Sodium Crystalline By Application : Tablets Chewable Tablet Oral Solution
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample